1.80Open1.80Pre Close0 Volume1 Open Interest2.00Strike Price0.00Turnover0.00%IV-8.87%PremiumDec 20, 2024Expiry Date2.17Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.32Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Trevi Therapeutics Stock Discussion
📊⚡️📊
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Thursday, 12th December at 7:30 am
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 20...
Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
No comment yet